Friday broker round-up
(Sharecast News) - William Hill: Peel Hunt upgrades to hold with a target price of 305p.
Read moreMon, 13th Feb 2017 08:21
(Sharecast News) - William Hill: Peel Hunt upgrades to hold with a target price of 305p.
Read moreLONDON (Alliance News) - Evgen Pharma PLC said Thursday it expects to receive the final read-out from two clinical trials by the end of 2018.The drug development company said at its annual
Read more(Sharecast News) - Clinical-stage drug development company Evgen Pharma has concluded patient recruitment in its STEM Phase IIa trial of SFX-01 in metastatic breast cancer, it announced on Wednesday.
Read more(Sharecast News) - Unite Group: Numis downgrades to hold with a target price of 900p.
Read moreLONDON (Alliance News) - Evgen Pharma PLC said Wednesday it has concluded its patient recruitment for its STEM Phase IIa trial of SFX-01 in metastatic breast cancer.Following the favourable
Read moreFriday 20 JulyHomeserveKCOM GroupMonday 23 JulyEthernity Energy 24
Read moreLONDON (Alliance News) - Clinical drug development company Evgen Pharma PLC said Wednesday its annual loss narrowed in line with expectations.Evgen, which focuses on cancer and neurological
Read moreLONDON (Alliance News) - Evgen Pharma PLC said Monday its STEM trial showed "early signs of anti-tumour activity" in breast cancer patients.STEM is the company's study of in a
Read moreLONDON (Alliance News) - Drug development company Evgen Pharma said Wednesday that it has secured a European patent recognising its intellectual property for a method of stabilising sulforaphane,
Read moreLONDON (Alliance News) - Drug development company Evgen Pharma PLC has started a new research collaboration with Imperial College London focusing on SFX-01, the company's
Read more(ShareCast News) - Clinical-stage drug development company Evgen Pharma announced the appointment of experienced healthcare executive Richard Moulson as its chief financial officer on Tuesday. The AIM-traded firm said Moulson was joining immediately as CFO-designate for a handover period to 28 Febru
Read more(ShareCast News) - Evgen Pharma, a clinical stage drug development company focused on the treatment of cancer and neurological conditions, has received a positive interim safety review from the independent Data Safety Monitoring Board (DSMB) for its Phase II double-blind placebo-controlled SAS trial
Read more(ShareCast News) - Clinical stage drug development company Evgen Pharma announced on Wednesday that it has received a Clinical Trial Approval from the UK's regulatory agency for the commencement of its Phase II clinical trial of SFX-01 in breast cancer. The AIM-traded firm said patient recruitment w
Read more